Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2016-11-15 Interim / Quarterly Rep…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Results for third quarter 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Third Quarter Report 2016' for Photocure Group. It contains detailed financial statements, including income statements, balance sheet data, and management commentary on operational performance for the third quarter and year-to-date periods. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2016
2016-11-15 English
Photocure ASA: Results for third quarter 2016
Interim / Quarterly Report Classification · 100% confidence The document is a presentation titled 'Results of Third Quarter and First Nine Months 2016' for Photocure ASA. It contains detailed financial tables (Profit & Loss, Cash Flow, Balance Sheet), operational updates, and management commentary regarding the company's performance for the specified interim period. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2016
2016-11-15 English
Photocure ASA: Results for third quarter 2016
Earnings Release Classification · 100% confidence The document explicitly states "Photocure ASA: Results for third quarter 2016" and provides detailed financial figures (revenue, EBITDA, net profit) for Q3 2016, comparing them to Q3 2015. This content is characteristic of a periodic financial report covering a period shorter than a full year. The text also mentions that the company "will present its interim report today" and provides details for a conference call/webcast. This strongly indicates an Interim/Quarterly Report (IR). Although it mentions the full financial report and presentation are enclosed, the primary content provided is the summary of the quarterly results, fitting the IR definition better than just an RPA, given the substantial financial detail present. Q3 2016
2016-11-15 English
Photocure ASA: Presentation of the third quarter 2016 results
Report Publication Announcement Classification · 98% confidence The document is titled "Photocure ASA: Presentation of the third quarter 2016 results" and details the time, location, and method (webcast/conference call) for presenting the third-quarter results. It explicitly mentions the presentation of the 'third quarter report'. Since the document itself is an announcement about *when* and *how* the results presentation will occur, and it is very short (1852 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full Interim Report (IR) or Earnings Release (ER). It is announcing the publication/presentation event.
2016-11-09 English
Photocure ASA: New data presented on Blue Light Cystoscopy with Cysview®/Hexvix® at the Société Internationale d'Urologie (SIU) 2016 Annual meeting
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA dated October 25, 2016, announcing that new data regarding their product (Cysview®/Hexvix®) was presented at a medical conference (SIU 2016 Annual meeting). It details the findings (ePoster data) and includes quotes from the CEO. This type of announcement, which disseminates recent business or scientific updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general Regulatory Filings (RNS) or, if it were a presentation, Investor Presentation (IP). Since it is a news announcement about data presented at a third-party meeting, and it is not a formal financial report, earnings release, or management discussion, RNS is the most appropriate general regulatory announcement category. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Investor Presentation (IP) itself, but rather a press release *about* data presented at a meeting.
2016-10-25 English
Photocure: Repeat use of Blue Light Cystoscopy with Hexvix®/Cysview® shows excellent tolerability
Regulatory Filings Classification · 95% confidence The document is a press release dated September 28th, 2016, announcing the publication of a study regarding the safety of repeat use of a medical procedure (Blue Light Cystoscopy with Hexvix®/Cysview®). It contains quotes from the CEO and medical professionals, provides background on the disease (Bladder Cancer), and details about the product. This format—a news announcement about clinical data or company developments, often linking to an external source (the journal abstract)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a formal financial report (like 10-K or IR) but rather a specific announcement of positive clinical data, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) as it is a company announcement of material information. Given the context of financial reporting databases, announcements of clinical trial results or key operational news that aren't formal financial statements often fall under ER or RNS. Since it is not explicitly tied to quarterly earnings figures but is a significant operational/clinical update, RNS is a strong candidate, but ER often covers significant operational news releases. However, looking at the definitions, this is a specific announcement of a study result, which is often released outside of standard quarterly reporting cycles. It is not a transcript (CT), a presentation (IP), or a formal report (AR, IR). It is a general announcement of material information. I will classify it as RNS (Regulatory Filings) as the most appropriate general category for non-standard, material company announcements that don't fit the other specific categories like DIV, CAP, or ER (which usually focuses on financial metrics). The document length (5402 chars) is substantial enough that it is not just a brief link announcement (RPA).
2016-09-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.